Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 2/20 | 0.46 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29724343 | 0.84 | SSTR4 (0.43) | SSTR4KMT2AGAA | |
| SCHEMBL5846872 | 0.84 | SSTR4 (0.43) | SSTR4KMT2AGAA | |
| SCHEMBL5846881 | 0.84 | SSTR4 (0.43) | SSTR4KMT2AGAA | |
| SCHEMBL5846877 | 0.84 | SSTR4 (0.43) | SSTR4KMT2AGAA | |
| SCHEMBL18740900 | 0.83 | POLB (0.46) | GLSL3MBTL1KDM4EALDH1A1NPSR1 | |
| SCHEMBL14446933 | 0.81 | GLS (0.46) | GLSPSMB5CYP19A1SSTR4HTR2B | |
| SCHEMBL27432522 | 0.80 | GLS (0.48) | GLSPSMB5CYP19A1SSTR4HTR2B | |
| SCHEMBL12749158 | 0.80 | SSTR4 (0.44) | PSMB5CYP19A1SSTR4L3MBTL1NPC1 | |
| SCHEMBL10900420 | 0.80 | KMT2A (0.46) | CYP19A1L3MBTL1RAB9AHTR2BHCRTR2 | |
| SCHEMBL15211430 | 0.80 | ESR1 (0.42) | HTR2BKDM4EALDH1A1HPGDCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4681774-A2 | KHK INHIBITORS | Gilead Sciences, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| EP-4313967-B1 | KHK INHIBITORS | GILEAD SCIENCES INC (US) | 2025-11-12 | — | — | EP | disclosed |
| EP-4313967-A1 | KHK INHIBITORS | GILEAD SCIENCES, INC. (US) | 2024-02-07 | — | — | EP | disclosed |
| CN-117120429-A | KHK inhibitor | 吉利德科学公司 | 2023-11-24 | — | — | CN | disclosed |
| WO-2022212194-A1 | KHK INHIBITORS | GILEAD SCIENCES, INC. (US) | 2022-10-06 | — | — | WO | disclosed |
| US-10428017-B2 | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use | ABBVIE S.Á.R.L. (LU) | 2019-10-01 | — | — | US | disclosed |
| CN-109069470-A | Use of specific benzodihydrofuran lignans for inhibiting breast cancer cell metastasis | 杨宁荪 | 2018-12-21 | — | — | CN | disclosed |
| WO-2018154493-A1 | MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE | AbbVie S.à.r.l. (LU) | 2018-08-30 | — | — | WO | disclosed |
| US-20180244640-A1 | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use | ABBVIE S.Á.R.L. (LU) | 2018-08-30 | — | — | US | disclosed |
| CN-105294620-A | Synthetic method for 4-amino-5-chloro-2,3-dihydro-7-benzofurancarboxylic acid | SHANGHAI FAMO BIOTECHNOLOGY CO LTD | 2016-02-03 | — | — | CN | disclosed |
| US-20090318409-A1 | PYRROLIDINE INHIBITORS OF IAP | GENENTECH, INC. (US) | 2009-12-24 | — | — | US | disclosed |
| US-20090176822-A1 | PYRROLIDINE INHIBITORS OF IAP | GENENTECH, INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-20080146808-A1 | AZABICYCLO-OCTANE INHIBITORS OF IAP | GENENTECH, INC. (US) | 2008-06-19 | — | — | US | disclosed |
| US-20080146808-A1 | AZABICYCLO-OCTANE INHIBITORS OF IAP | GENENTECH, INC. (US) | 2008-06-19 | — | — | US | disclosed |
| US-7345081-B2 | Azabicyclo-octane inhibitors of IAP | GENENTECH, INC. (US) | 2008-03-18 | — | — | US | disclosed |
| US-7345081-B2 | Azabicyclo-octane inhibitors of IAP | GENENTECH, INC. (US) | 2008-03-18 | — | — | US | disclosed |
| CN-1214008-C | Therapeutic biaryl derivatives | GLAXO GROUP LTD (GB) | 2005-08-10 | — | — | CN | disclosed |
| CN-1312800-A | Therapeutic biaryl derivatives | GLAXO GROUP LTD (GB) | 2001-09-12 | — | — | CN | disclosed |
| CN-1020102-C | Process for producing bicyclic carboxylic acid ester and bicyclic carboxamide | EIL LILLY & CO (US) | 1993-03-17 | — | — | CN | disclosed |
| CN-1031841-A | The improvement of special 5-HT3 antagonist | LILLY CO ELI (US) | 1989-03-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10428017-B2 | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use | CFTR, CLCN2, SCNN1G | GLS 1373/4885PSMB5 2724/4885CYP19A1 4872/4885 |
| US-20090176822-A1 | PYRROLIDINE INHIBITORS OF IAP | BIRC5, XIAP, BIRC2 | GLS 1282/4885PSMB5 132/4885CYP19A1 4494/4885 |
| US-20080146808-A1 | AZABICYCLO-OCTANE INHIBITORS OF IAP | XIAP, BIRC3, BIRC2 | GLS 3179/4885PSMB5 172/4885CYP19A1 3097/4885 |
| US-20180244640-A1 | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use | CFTR, CLCN2, SCNN1G | GLS 1373/4885PSMB5 2724/4885CYP19A1 4872/4885 |
| US-20090318409-A1 | PYRROLIDINE INHIBITORS OF IAP | BIRC5, XIAP, BIRC2 | GLS 1282/4885PSMB5 132/4885CYP19A1 4494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.